Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|270-9139|4|1047-1058

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.270-9139, Iss.4, 2015-10, pp. : 1047-1058

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1047-1058

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sofosbuvir with peginterferon‐ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

By  

HEPATOLOGY, Vol. 61, Iss. 3, 2015-03 ,pp. : 769-775

John Wiley & Sons Inc

Access to resources Recommend Favorite

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1013-1023

John Wiley & Sons Inc

Access to resources Recommend Favorite

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1013-1023

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 25-30

John Wiley & Sons Inc

Access to resources Recommend Favorite